DPC News

FDA Authorizes 23andMe DTC Test Report for Three BRCA Mutations

Whole Genome Sequencing FOR DOCTORS taught by the Faculty of Concierge Medicine Today/DPC Journal Atlanta, GA OCTOBER “FORUM” — Join Precision Medicine Physicians, thought leaders and others in ATLANTA, GA USA to learn more about the impact and intersection of Primary Care Physicians and your Patient’s DNA and Genetic Test Reports, October 26-27, 2018 .. REGISTER HERE …

FDA News Release

FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes

Test only reports 3 out of more than 1,000 known BRCA mutations and negative result doesn’t rule out increased cancer risk.

For Immediate Release

“A first-rate, translational medicine scientist [e.g. speaking about one of the Genome Lecturers on Friday, October 27th] is also a first-rate teacher of practicing physicians about the most timely and important current clinical topic.” ~S.B., MD., 2017 Physician Attendee, Arizona — (Photo: Dr. Brandon Colby, CMT Faculty Member; Founder, Sequencing.com) — Whole Genome Sequencing FOR DOCTORS taught by the Faculty of Concierge Medicine Today/DPC Journal Atlanta, GA OCTOBER “FORUM” — Join Precision Medicine Physicians, thought leaders and others in ATLANTA, GA USA to learn more about the impact and intersection of Primary Care Physicians and your Patient’s DNA and Genetic Test Reports, October 26-27, 2018 .. REGISTER HERE … SUPER EARLY BIRD DISCOUNTS NOW AVAILABLE …

March 6, 2018

The U.S. Food and Drug Administration today authorized the Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants). It is the first direct-to-consumer (DTC) test to report on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in people of Ashkenazi (Eastern European) Jewish descent. These three mutations, however, are not the most common BRCA1/BRCA2 mutations in the general population.

RELATED STORY
Official POSITION STATEMENT on Whole Genome Sequencing Vs. Limited Genetic Testing, Concierge Medicine Today

The test analyzes DNA collected from a self-collected saliva sample, and the report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The test only detects three out of more than 1,000 known BRCA mutations. This means a negative result does not rule out the possibility that an individual carries other BRCA mutations that increase cancer risk.

“This test provides information to certain individuals who may be at increased breast, ovarian or prostate cancer risk and who might not otherwise get genetic screening, and is a step forward in the availability of DTC genetic tests. But it has a lot of caveats,” said Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “While the detection of a BRCA mutation on this test does indicate an increased risk, only a small percentage of Americans carry one of these three mutations and most BRCA mutations that increase an individual’s risk are not detected by this test. The test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk.”

Consumers and health care professionals should not use the test results to determine any treatments, including anti-hormone therapies and prophylactic removal of the breasts or ovaries. Such decisions require confirmatory testing and genetic counseling. The test also does not provide information on a person’s overall risk of developing any type of cancer. The use of the test carries significant risks if individuals use the test results without consulting a physician or genetic counselor.

WATCH — EDITOR’S REVIEW of DNA TESTS & WHOLE GENOME SEQUENCING, 2018 — CMT talks types Concierge Medicine, Your waiting room and More on our New FOR DOCTORS YouTube Channel … Click Here to WATCH ALL Playlist …

RELATED INTERVIEW | NATIONAL | GENOMICS EDUCATION for PHYSICIANS

DocPreneur PODCAST, EP. 100 | “Genetic Testing 101” An Interview with Geneticist, Author and CEO, Brandon Colby, MD

DOCPRENEUR PODCAST — What is a PGX TEST?  What is Pharmacogenomics? How does it apply to your Membership Medicine style Practice? What type of REPORTS are made available to the Patient and to the Doctor? Learn More …

The three BRCA1/BRCA2 hereditary mutations detected by the test are present in about 2 percent of Ashkenazi Jewish women, according to a National Cancer Institute study, but rarely occur (0 percent to 0.1 percent) in other ethnic populations. All individuals, whether they are of Ashkenazi Jewish descent or not, may have other mutations in BRCA1 or BRCA2 genes, or other cancer-related gene mutations that are not detected by this test. For this reason, a negative test result could still mean that a person has an increased risk of cancer due to gene mutations.  Additionally, most cases of cancer are not caused by hereditary gene mutations but are thought to be caused by a wide variety of factors, including smoking, obesity, hormone use and other lifestyle issues. For all of these reasons, it is important for patients to consult their health care professional who can help them understand how these factors impact their individual cancer risk and what they can do to modify that risk.

The FDA’s review of the test determined among other things that the company provided sufficient data to show that the test is accurate (i.e., can correctly identify the three genetic variants in saliva samples), and can provide reproducible results. The company submitted data on user comprehension studies, using representative GHR test reports, that showed instructions and reports were generally easy to follow and understood by a consumer. The test report provides information describing what the results might mean, how to interpret results and where additional information about the results may be found.

RELATED STORY
OFFICIAL POSITION, STATEMENT: Support For Use of Whole Genome Sequencing in Concierge Medicine

ORDER YOUR WHOLE GENOME TEST (Reg. $4,999, NOW $1,999) — Learn More about WHOLE GENOME SEQUENCING and DNA Testing for Physicians and Your Patients …

The FDA reviewed data for the test through the de novo premarket review pathway, a regulatory pathway for novel, low-to-moderate-risk devices that are not substantially equivalent to an already legally marketed device. Along with this authorization, the FDA is establishing criteria, called special controls, which set forth the agency’s expectations in assuring the test’s accuracy, reproducibility, clinical performance and labeling. These special controls, when met along with general controls, provide reasonable assurance of safety and effectiveness for this test.

The FDA granted the marketing authorization to 23andMe.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

###

SOURCE: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599560.htm

Advertisements

Categories: DPC News

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s